New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:19 EDTICPTIntercept shares more than double in pre-market after NASH primary endpoint met
Shares of Intercept Pharmaceuticals are up about 140% to $173.00 in pre-market trading after the company announced that the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH, has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. Intercept closed trading yesterday at $72.39.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:59 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
April 12, 2014
20:04 EDTICPTIntercept reports additional positive data from POISE trial at EASL
Subscribe for More Information
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use